April 27 (Reuters) - Roche
* Drugs head Dan O'Day says access limitations for multiple sclerosis medicine Ocrevus in United States 'are really none'
* Says he is hopeful ACE910 will be available to hemophilia patients by end of 2017, early 2018
* O'Day says has seen no more significant thromboembolic events with ACE910 beyond those already reported
* Says Lucentis sales seen rising in FY2017, though pace may slow from 9 percent in first quarter Source text for Eikon: Further company coverage: (Reporting by John Miller)